Gilead Sciences Inc. (NASDAQ:GILD) is one of Goldman Sachs top healthcare stocks. On March 10, Jefferies initiated coverage of Gilead Sciences Inc. (NASDAQ:GILD) with a Buy rating and a $180 price target. The research firm has touted the company’s earnings-per-share growth and margin-expansion prospects as part of its bullish thesis.
kurhan / shutterstock.com
According to the research firm, the company is not facing any near-term intellectual property cliffs or significant operating leverage. Instead, it is well positioned with its HIV franchise and the prospects for follow-on products. The research firm is also optimistic about the company’s prospects with the launch of Yetzugo in pre-exposure prophylaxis.
In addition, Gilead Sciences is making significant progress on its pipeline development. A phase 3 RAINIER trial for drug povetacicept has already met primary and secondary endpoints in treating immunoglobulin A nephropathy (IgAN).
Amid the pipeline development, Gilead has also inked a $7.8 billion deal to acquire blood cancer drug developer Arcellx. The deal follows a long partnership, signed in 2022, for the commercialization of medicines to combat multiple myeloma.
Gilead Sciences, Inc. (NASDAQ:GILD) is a US-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines for life-threatening diseases, particularly in virology, oncology, and inflammation. It is known for its leadership in antiviral therapies for HIV, Hepatitis B and C, and COVID-19, with a strong focus on expanding its impact globally, including in Asia.
While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Affordable Growth Stocks to Buy Now.
Disclosure: None. Follow Insider Monkey on Google News.
